Literature DB >> 4155336

The haemodynamic effects of prolonged oral administration of oxyfedrine, a partial agonist at beta-adrenoceptors: comparison with propranolol.

J R Parratt.   

Abstract

1 Haemodynamic changes have been studied in cats after the chronic oral administration of oxyfedrine (14 mg/kg for 3-4 weeks) or of placebo (lactose). The initial part of the study was carried out under double-blind conditions. The arterial blood pressure was between 19 mmHg (diastolic) and 27 mmHg (systolic) higher in the oxyfedrine treated animals, but there were no differences between the two groups with regard to cardiac output, left ventricular dP/dt max, heart rate or systolic ejection time.2 In cats similarly treated with propranolol (4 mg/kg) there was a slight (12%), but significant, reduction in cardiac output.3 Isoprenaline dose-response curves were shifted to the right in the cats administered oxyfedrine as well as in those administered propranolol. The degree of shift was five-fold (positive chronotropic response) and 20-fold (decrease in diastolic blood pressure) in the oxyfedrine group and 10- and 80-fold, respectively, in the propranolol group.4 In contrast to the partial blockade of the effects of isoprenaline, the haemodynamic response to oxyfedrine was largely unaltered, both in the cats pretreated with propranolol and in those pretreated with oxyfedrine. The pressor response to noradrenaline was potentiated in the cats pretreated with oxyfedrine.5 These results provide an explanation for the anti-anginal action of oxyfedrine. Some degree of beta-adrenoceptor blockade is achieved without a reduction in cardiac output or left ventricular dP/dt max. The relevance of these findings to the haemodynamic situation in angina is discussed.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4155336      PMCID: PMC1776796          DOI: 10.1111/j.1476-5381.1974.tb09625.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  [Experiences with Ildamen in double placebo experiments].

Authors:  E Stampfer
Journal:  Wien Klin Wochenschr       Date:  1969-04-18       Impact factor: 1.704

2.  [The management of angina pectoris using Ildamen, a new coronary- and cardiac-active substance, in a double-blind study].

Authors:  S Greif; V Liertzer
Journal:  Arztl Forsch       Date:  1967-09-10

Review 3.  Perspectives in adrenergic beta-receptor blockade.

Authors:  J D Fitzgerald
Journal:  Clin Pharmacol Ther       Date:  1969 May-Jun       Impact factor: 6.875

4.  A method for the calculation of areas under indicator-dilution curves.

Authors:  J C Williams; T P O'Donovan; E H Wood
Journal:  J Appl Physiol       Date:  1966-03       Impact factor: 3.531

5.  Cardiac effects of oxyfedrine in the cat.

Authors:  A R Thalinger; A M Lefer
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

6.  The effect of adrenaline, noradrenaline, and propranolol on myocardial blood flow and metabolic heat production in monkeys and baboons.

Authors:  J R Parratt
Journal:  Cardiovasc Res       Date:  1969-07       Impact factor: 10.787

7.  Blood gas calculator.

Authors:  J W Severinghaus
Journal:  J Appl Physiol       Date:  1966-05       Impact factor: 3.531

8.  The effect of propranolol on the cardiovascular responses to isoprenaline, adrenaline and noradrenaline in the anaesthetized dog.

Authors:  R G Shanks
Journal:  Br J Pharmacol Chemother       Date:  1966-02

9.  Hemodynamic effects of propranolol and H 56-28 in man--comparative study of two beta-adrenergic receptor antagonists.

Authors:  S A Forsberg; G Johnsson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1967

10.  The effect of catecholamine infusions on myocardial blood flow, metabolic heat production and on general haemodynamics, before and after alprenolol (H56-28), in anaesthetized cats.

Authors:  J R Parratt; R M Wadsworth
Journal:  Br J Pharmacol       Date:  1970-05       Impact factor: 8.739

View more
  7 in total

1.  Potentation of the cardiac response to aminophylline by oxyfedrine.

Authors:  K Sakai; G Pöch; W R Kukovetz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

2.  Prostaglandins and thromboxane in the delayed phase of shock induced by Serratia marcescens endotoxin.

Authors:  J R Parratt; N Sharma; I J Zeitlin
Journal:  Br J Pharmacol       Date:  1984-05       Impact factor: 8.739

3.  The cardiovascular pharmacology of 7-propyl-theo-phylline-dopamine (D4975); comparison with dopamine and dobutamine.

Authors:  D McCaig; J R Parratt
Journal:  Br J Pharmacol       Date:  1979-10       Impact factor: 8.739

4.  Comparison of oxyfedrine and atenolol in angina pectoris--a double-blind study.

Authors:  L Fananapazir; C Bray
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

5.  Effects of oxyfedrine on regional myocardial blood flow in patients with coronary artery disease.

Authors:  J C Kaski; L Araujo; A Maseri
Journal:  Cardiovasc Drugs Ther       Date:  1991-12       Impact factor: 3.727

6.  A comparison of the cardiovascular effects of dobutamine and a new dopamine derivative (D4975) during shock induced by E. coli endotoxin.

Authors:  D McCaig; J R Parratt
Journal:  Br J Pharmacol       Date:  1980-08       Impact factor: 8.739

Review 7.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.